A comprehensive systematic review of leishmaniasis in patients undergoing drug-induced immunosuppression for the treatment of dermatological, rheumatological and gastroenterological diseases

Authors

  • Patrícia Shu Kurizky Universidade de Brasília, Faculdade de Medicina, Programa de Pós-Graduação em Ciências Médicas
  • Fernanda Ferraço Marianelli Hospital Universitário de Brasília
  • Mariana Vicente Cesetti Universidade de Brasília, Faculdade de Medicina, Programa de Pós-Graduação em Ciências Médicas
  • Giovanni Damiani Case Western Reserve University, Department of Dermatology
  • Raimunda Nonata Ribeiro Sampaio Universidade de Brasília, Faculdade de Medicina, Programa de Pós-Graduação em Ciências Médicas
  • Lais Mitsue Tanaka Gonçalves Hospital Universitário de Brasília
  • Carlos Augusto Felipe de Sousa Universidade de Brasília, Faculdade de Medicina, Programa de Pós-Graduação em Ciências Médicas
  • Sofia Sales Martins Universidade de Brasília, Faculdade de Ciências da Saúde
  • Sebastian Vernal Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Departamento de Clínica Médica
  • Licia Maria Henrique da Mota Universidade de Brasília, Faculdade de Medicina, Programa de Pós-Graduação em Ciências Médicas
  • Ciro Martins Gomes Universidade de Brasília, Faculdade de Medicina, Programa de Pós-Graduação em Ciências Médicas https://orcid.org/0000-0002-3069-6884

DOI:

https://doi.org/10.1590/S1678-9946202062028

Keywords:

Immunosuppression, Leishmaniasis, Systematic review, Treatment

Abstract

Immunosuppression is an important risk factor for leishmaniasis. We assessed the clinical profile, geographic distribution and prevalence of leishmaniasis in patients undergoing immunosuppressive therapy for dermatological, rheumatological or gastroenterological autoimmune diseases. We identified relevant studies in PubMed, EMBASE, Scopus, Web of Science and LILACS on July 3rd, 2018. We included articles that reported at least one case of leishmaniasis in patients undergoing immunosuppressive treatment for dermatological, rheumatological or gastroenterological diseases. Our protocol was registered in PROSPERO (CRD42018103050). We assessed the quality of the included studies with the Joanna Briggs Institute Critical Appraisal Tool. After the removal of duplicates, 5,431 articles were collected and screened. We included 138 articles; the prevalence of leishmaniasis in six methodologically similar studies varied from three to 1,282 cases per 100,000 patients using anti-TNFα drugs, but the results were significantly heterogeneous . Leishmaniasis in patients treated with immunosuppressive drugs is a health problem mostly reported in European countries bordering the Mediterranean Sea; sporadic activities, such as travelling, seem not to be associated with a significant risk of leishmaniasis, although effective control measures must always be observed.

Downloads

Download data is not yet available.

Downloads

Published

2020-05-09

Issue

Section

Original Articles

How to Cite

A comprehensive systematic review of leishmaniasis in patients undergoing drug-induced immunosuppression for the treatment of dermatological, rheumatological and gastroenterological diseases. (2020). Revista Do Instituto De Medicina Tropical De São Paulo, 62, e28. https://doi.org/10.1590/S1678-9946202062028